Miyakoda G, Nakayama N, Matsui K, Yabuuchi Y
2nd Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., Japan.
Arzneimittelforschung. 1995 Apr;45(4):471-5.
To elucidate the mechanisms of the potent and long-lasting antihypertensive action of pranidipine (CAS 99522-79-9, OPC-13340), a wash-out experiment in isolated rat aorta preparations and a displacement binding experiment of (+)[3H]PN200-110 (isradipine) with pranidipine and other dihydropyridines to porcine skeletal T-tubules was conducted. It was revealed that the inhibition of KCl-induced contraction by pranidipine remained complete even after washing out the drug 9 times. Also, pranidipine had the lowest Ki value for (+)[3H]PN200-110 binding in skeletal T-tubules. The lipophilicity of pranidipine measured by octanol-buffer partition coefficient was the highest among the tested compounds, and the order of lipophilicity coincided with the order of potency in the displacement binding experiments. These results suggest that pranidipine has a very high affinity to Ca channels or to T-tubule membranes, and strongly support the "membrane-bilayer pathway hypothesis" which assumes the partitioning of the drug into the lipid bilayer before drug binding to Ca channels as an explanation of the potent and long-lasting action of pranidipine compared with other dihydropyridines.
为阐明普拉地平(CAS 99522-79-9,OPC-13340)强效且持久的降压作用机制,进行了大鼠离体主动脉标本的洗脱实验,以及用普拉地平和其他二氢吡啶对猪骨骼肌T小管进行的(+)[3H]PN200-110(伊拉地平)置换结合实验。结果显示,即使在洗脱药物9次后,普拉地平对氯化钾诱导收缩的抑制作用仍完全存在。此外,普拉地平在骨骼肌T小管中对(+)[3H]PN200-110结合的Ki值最低。通过正辛醇-缓冲液分配系数测定的普拉地平的亲脂性在受试化合物中最高,亲脂性顺序与置换结合实验中的效价顺序一致。这些结果表明,普拉地平对钙通道或T小管膜具有非常高的亲和力,并有力地支持了“膜双层途径假说”,该假说认为药物在与钙通道结合之前先分配到脂质双层中,以此解释普拉地平与其他二氢吡啶相比具有强效且持久作用的原因。